Sources Say Riverbed is Not Considering a Sale

was rumored to have hired Goldman Sachs to consider a possible sale following a stock surge of more than $1.50 ahead of Wednesday's closing bell. Last night, Reuters reported that Riverbed in not currently weighing a sale after interviewing two sources. Reuter's Nicola Leske noted, "the two sources told Reuters that while GoldmanSachs had been a long time advisor to Riverbed, the bank is currently not working with the company on a potential sale. Representatives of Riverbed and Goldman Sachs declined to comment. The sources asked not to be named because the matter is not public." On November 11th, Riverbed Technology's board of director's approved a "poison pill" stockholder plan, which will kick in when an investor has a 10% stake in the company or an institution owns 20% of shares. This plan was shortly adopted following activist investor Elliot Management's obtained a 10.4% stake and suggested that the shares are undervalues and recommended a strategic review. Riverbed Technology closed at $19.04 on Wednesday and is currently trading -5.25%.